<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04296175</url>
  </required_header>
  <id_info>
    <org_study_id>1807187-2</org_study_id>
    <nct_id>NCT04296175</nct_id>
  </id_info>
  <brief_title>Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)</brief_title>
  <acronym>CITRINE</acronym>
  <official_title>A Prospective, Single Center, Randomized, Open-labled Stage III Clinical Trial Comparing the Efficacy and Safety of Anthracyclin Followed by Weekly Paclitaxel Versus Dose-dense Anthracyclin Followed by Weekly Paclitaxel Versus Dose-dense Anthracyclin Followed by Weekly Paclitaxel Combined With Carboplatin for High-risk, Triple-negative Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single center, randomized, open-labled stage III clinical trial
      comparing the efficacy and safety of anthracyclin followed by weekly paclitaxel versus
      dose-dense anthracyclin followed by weekly paclitaxel versus dose-dense anthracyclin followed
      by weekly paclitaxel combined with carboplatin for high-risk, triple-negative early breast
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single center, randomized, open-labled stage III clinical trial
      comparing the efficacy and safety of anthracyclin followed by weekly paclitaxel versus
      dose-dense anthracyclin followed by weekly paclitaxel versus dose-dense anthracyclin followed
      by weekly paclitaxel combined with carboplatin for high-risk, triple-negative early breast
      cancer.High risk is defined as positive lymph nodes or negative lymph nodes but ki-67 is not
      less than 50%. We aim to explore whether the addition of carboplatin can improve the
      disease-free survival of early high-risk triple-negative breast cancer. At the same time, the
      experimental group's anthracyclines must be given in a dose-dense manner, while
      anthracyclines in the control group are dose-dense or not.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant disease free survival</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence free survival</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence free survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant disease free survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">808</enrollment>
  <condition>Triple-negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>conventional group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>epirubincin 90mg/m2 d1 and CTX 600mg/m2 d1, every 2 or 3 weeks followed by paclitaxel 80mg/m2 d1,d8,d15, every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>carboplatin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>epirubincin 90mg/m2 d1 and CTX 600mg/m2 d1, every 2 weeks followed by paclitaxel 80mg/m2 and carboplatin AUC=2 d1,d8,d15, every 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>90mg/m2, d1 every 2 or 3 weeks</description>
    <arm_group_label>conventional group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTX</intervention_name>
    <description>600mg, d1 every 2 or 3 weeks</description>
    <arm_group_label>conventional group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>80mg/m2,d1,d8,d15, every 3 weeks</description>
    <arm_group_label>conventional group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ddEpirubicin</intervention_name>
    <description>90mg/m2, d1 every 2 weeks</description>
    <arm_group_label>carboplatin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ddCTX</intervention_name>
    <description>600mg, d1 every 2 weeks</description>
    <arm_group_label>carboplatin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel(with carbo)</intervention_name>
    <description>80mg/m2,d1,d8,d15, every 4 weeks</description>
    <arm_group_label>carboplatin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC=2,d1,d8,d15, every 4 weeks</description>
    <arm_group_label>carboplatin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

          2. Histologically documented TNBC after early breast cancer surgery (absence of HER2, ER,
             and PR expression)

          3. Has adequate organ function meeting the following criteria: (1) adequate bone marrow
             function: hemoglobin ≥ 90 g/L (no blood transfusion within 14 days); absolute
             neutrophil count ≥ 1.5 x 109 /L; platelet count ≥ 75 * 109 /L; (2)adequate liver and
             kidney function: Alanine Aminotransferase (ALT) ≤ 3×upper limit of normal (ULN),
             Aspartate Aminotransferase (AST) ≤ 3×ULN, Total Bilirubin (TBIL)≤ 1.5×ULN, serum
             creatinine ≤ 1×ULN#and with endogenous creatinine clearance rate of &gt;50 ml/min
             (Cockcroft-Gault formula).

          4. Women aged 18-70 years old;

          5. Lymph nodes positive or lymph nodes negative but with ki67 no less than 50%

          6. Have the cognitive ability to understand the protocol and be willing to participate
             and to be followed up

          7. For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use contraceptive measures as outlined for each specific
             treatment arm

        Exclusion Criteria:

          1. Has received neoadjuvant therapy (include chemotherapy, targeted therapy, radiotherapy
             or endocrine therapy;

          2. Has bilateral breast cancer;

          3. Has previous history of additional malignancy, with the exception of adequately
             treated basal cell carcinoma and cervical carcinoma in situ.

          4. Has metastatic breast cancer

          5. Is pregnant, is breast feeding women, or women of childbearing age who cannot practice
             effective contraceptives;

          6. Patients participating in other clinical trials at the same time;

          7. Has severe organ dysfunction (cardiopulmonary liver and kidney) insufficiency, left
             ventricular ejection fraction (LVEF) &lt; 50% (cardiac ultrasound); severe cardio
             cerebral vascular disease within the 6 months previous of randomization (such as
             unstable angina, chronic heart failure, uncontrolled hypertension with blood
             pressure&gt;150/90mmgh, myocardial infarction, or cerebral blood vessel); diabetic
             patients with poor blood glucose control; patients with severe hypertension;

          8. Has known allergy to taxane

          9. Has severe or uncontrolled infection;

         10. Has a history of psychotropic substance abuse and were unable to abandon drug habits,
             or those with history of mental disorders;

         11. the researchers judged patients to be unsuitable for the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhimin Shao, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhimin Shao, Professor</last_name>
    <phone>08664175590</phone>
    <phone_ext>88807</phone_ext>
    <email>zhimingshao@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhonghua Wang, Professor</last_name>
    <phone>08664175590</phone>
    <phone_ext>88603</phone_ext>
    <email>zhonghuawang95@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhimin Shao, M.D.</last_name>
      <phone>08664175590</phone>
      <phone_ext>88807</phone_ext>
      <email>zhimingshao@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Yin Liu, M.D.</last_name>
      <phone>08664175590</phone>
      <phone_ext>88603</phone_ext>
      <email>liuyinfudan@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 3, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhimin Shao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>dose-dense chemotherapy</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>High-risk, Triple-negative Early Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

